Study of PCSK9 protein level in plasma of hyperlipidaemia patients by western blot method

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a predicted target for pharmacological treatment in hyperlipidemia and cardiovascular disease because it acts as a serine protease and is known to control plasma low density lipoprotein (LDL-C) levels). PCSK9 plasma concentration was analyzed for people diagnosed with hyperlipidemia by Western blotting in this study. Especially hyperlipidemia with the prominence of elevated cholesterol and triglycerides is one of the leading causes of atherosclerosis along with cardiovascular morbidity and mortality. The upregulation of PCSK9 is revealed to be associated with increased levels of LDL-C due to its action on modulating the degradation of LDL receptors. 60 hyperlipidemic patients taking part in the research and 30 normolipidemic controls had their blood plasma collected for analysis. Quantifying protein extracts with SDS-PAGE electrophoresis followed by immunoblotting detection of PCSK9 with anti-PCSK9 monoclonal antibodies were used to determine the level of PCSK9. Expressing PCSK9 to be statistically more elevated in hyperlipidemic patients when compared with controls has proven to be correct. Not to mention that PCSK9 expression also correlates with the total cholesterol amount and the total concentration of LDL-C. As a result of regulation of dyslipidemia PCSK9 regulation has the potential do prove its reliability with a relatively simple method in quantifying PCSK9 in plasma suggest the utility of Western blotting. The development of PCSK9 as a biosign would facilitate and alter the approach toward treatment of hyperlipidemia.